Literature DB >> 31843623

DaBlaCa-11: Photodynamic Diagnosis in Flexible Cystoscopy-A Randomized Study With Focus on Recurrence.

Ditte Drejer1, Anne-Louise Moltke2, Anna Munk Nielsen3, Gitte W Lam4, Jørgen Bjerggaard Jensen5.   

Abstract

OBJECTIVE: To examine whether photodynamic diagnosis (PDD) in addition to flexible cystoscopy in the outpatient clinic can reduce risk of tumor recurrence in patients with previous nonmuscle invasive bladder cancer. PDD is an optical technique that enhances the visibility of pathologic tissue and helps guidance tumor resection.
METHODS: From February 2016 to December 2017, 699 patients from 3 urologic departments in Denmark were enrolled in a randomized controlled trial. Four months after transurethral resection of bladder tumor patients were randomized 1:1 to either an intervention group (hexaminolevulinate was instilled in the bladder before flexible cystoscopy with PDD video cystoscope) or a control group (white light flexible cystoscope), only. Primary endpoint was tumor recurrence within 8 months from the randomization. Secondary outcomes were numbers of procedures in general anesthesia, time to the first recurrence, differences in tumor size, risk of tumor progression, and identification of carcinoma in situ.
RESULTS: A total of 351 patients were allocated to the intervention group (flexible PDD), and 348 to the control group (flexible white light). Throughout the following 8 months after randomization, only 117 patients in the intervention group had at least 1 tumor recurrence compared to 143 patients in the control group (P = .049). Odds ratio of 0.67 (P = .02, 95% CI: 0.48-0.95) correlates with a tumor reduction of 33% in favor of the intervention group.
CONCLUSION: Use of PDD in a routine surveillance cystoscopy first time after transurethral resection of bladder tumor for nonmuscle invasive bladder cancer reduces subsequent risk of tumor recurrence compared to WL cystoscopy alone.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31843623     DOI: 10.1016/j.urology.2019.12.002

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

Review 1.  Advances in Diagnosis and Therapy for Bladder Cancer.

Authors:  Xinzi Hu; Guangzhi Li; Song Wu
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

Review 2.  Blue versus white light for transurethral resection of non-muscle invasive bladder cancer.

Authors:  Philipp Maisch; Alex Koziarz; Jon Vajgrt; Vikram Narayan; Myung Ha Kim; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2021-12-01

Review 3.  Role of Macroscopic Image Enhancement in Diagnosis of Non-Muscle-Invasive Bladder Cancer: An Analytical Review.

Authors:  Prashant Motiram Mulawkar; Gyanendra Sharma; Ashwin Tamhankar; Utsav Shah; Rickaz Raheem
Journal:  Front Surg       Date:  2022-02-21

Review 4.  Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?

Authors:  Nada Humayun-Zakaria; Douglas G Ward; Roland Arnold; Richard T Bryan
Journal:  Transl Androl Urol       Date:  2021-06

5.  Novel Visualization Methods Assisted Transurethral Resection for Bladder Cancer: An Updated Survival-Based Systematic Review and Meta-Analysis.

Authors:  Honglin Li; Yubin Cao; Pingchuan Ma; Zhongkai Ma; Chunjie Li; Wenbin Yang; Lingyun Zhou
Journal:  Front Oncol       Date:  2021-07-13       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.